Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications.
Quinn explains how they plan to expand skin biotics technology into oral and healthcare as well as establish a 'physical footprint of a lab'.
The funds will also be invested to expand the group’s research capabilities by adding its own facilities to those it uses at the University of Manchester.
